IceCure’s Shares Jump 27% on 42% ProSense® Sales Surge and FDA Advisory Nod

Introduction

ICECURE MEDICAL LTD (NASDAQ: ICCM), known in Korean as 아이스큐어 메디컬, develops and markets minimally invasive cryoablation systems for the treatment of benign and malignant tumors. As of August 28, 2025, the stock closed at $1.2550, an increase of 27.40% on a trading volume of 5,032,053 shares on the NASDAQ.

Corporate Structure and Experience

Founded in 2006 and headquartered in Caesarea, Israel, IceCure Medical employs between 51 and 200 professionals. The company’s leadership combines medical-device R&D expertise from firms such as GE Healthcare with experienced executives in commercial roles. In January 2025, Vic Lee, Chairman of VI Asset Management, joined the Board of Directors to support strategic initiatives in minimally invasive oncology.

Cryoablation by 兆航 樊

Developments and News

• January 13, 2025: In a letter to shareholders, CEO Eyal Shamir reported a 42% increase in ProSense® sales in North America for 2024. Revenues from ProSense system and disposable probes rose to $3.19 million, compared to $2.96 million in 2023. Total revenues increased to $3.29 million from $3.23 million, and cash and cash equivalents were approximately $7.5 million as of December 31, 2024.
• January 2025: An FDA Medical Device Advisory Committee voted nine-to-five in favor of ProSense’s benefit-risk profile for early-stage low-risk breast cancer, contingent on certain special controls.
• Q1 2025 (expected): FDA decision on marketing authorization of ProSense for early-stage breast cancer anticipated.
• August 20, 2025: At the Annual and Special General Meeting of Shareholders, all agenda items were approved, confirming a quorum and compliance with regulatory requirements under Forms F-3 and S-8.

Financial and Strategic Analysis

IceCure Medical’s performance in 2024 highlights revenue growth alongside continued investment in clinical validation:

• System and probe sales: $3.19 million (2024) vs. $2.96 million (2023)
• Total revenues: $3.29 million (2024) vs. $3.23 million (2023)
• Cash balance: ~$7.5 million at December 31, 2024
• Trailing-twelve-month net loss: approximately $14 million
• Market capitalization: ~$85.8 million
• Debt: none reported

Analysts foresee potential breakeven by 2027, projecting an average revenue growth rate of approximately 51% annually. The company’s lack of debt supports liquidity while it pursues FDA clearance and broader market presence.

Market Position and Industry Context

IceCure’s ProSense Cryoablation System employs liquid nitrogen to reach ultra-low temperatures (–160 °C ± 10 °C) using a single cryoprobe. Key clinical milestones include:

• ICE3 Trial: This was the largest controlled multi-center study of liquid nitrogen cryoablation for low-risk breast tumors, reporting a 96.3% five-year recurrence-free rate and 100% satisfaction among patients and physicians.
• Regulatory Status: CE marked for select markets; FDA-cleared for benign and specific malignant tumors; current review by the FDA for early-stage breast cancer indication.

By providing office-based, minimally invasive treatment options, IceCure seeks to address the trend toward surgical de-escalation in oncology, positioning itself in relation to traditional lumpectomy and other ablative technologies.

tl;dr

On January 13, 2025, IceCure reported a 42% increase in North American ProSense® sales, concluding 2024 with revenues of $3.29 million and cash totaling $7.5 million at year-end. An FDA Advisory Panel voted in January 2025 in favor of ProSense’s benefit-risk profile for early-stage breast cancer, with a regulatory decision expected in Q1 2025. The stock rose 27.40% to $1.2550 on August 28, 2025. Shareholders approved all items at the August 20, 2025 meeting. Analysts anticipate breakeven in 2027, supported by ongoing clinical validation and market expansion efforts.